Bansal, ShwetaCanziani, María E.F.Birne, RitaAnker, Stefan D.Bakris, GeorgeFilippatos, Gerasimos S.Rossing, PeterRuilope Urioste, Luis MiguelKolkhof, PeterLage, AndreaEt al.2025-07-312025-07-312024Bansal, S., Canziani, M. E. F., Birne, R., Anker, S. D., Bakris, G. L., Filippatos, G., Rossing, P., Ruilope, L. M., Farjat, A. E., Kolkhof, P., Lage, A., Brinker, M., & Pitt, B. (2024). Finerenone cardiovascular and kidney outcomes by age and sex: FIDELITY post hoc analysis of two phase 3, multicentre, double-blind trials. BMJ Open, 14(3), e076444. https://doi.org/10.1136/bmjopen-2023-0764442044-6055https://hdl.handle.net/11268/16064This study aimed to evaluate the efficacy and safety of finerenone, a selective, non- steroidal mineralocorticoid receptor antagonist, on cardiovascular and kidney outcomes by age and/or sex. In patients with diabetes, the risk of cardiovascular (CV) disease and chronic kidney disease (CKD) increases with age.1 Likewise, vascular complications are affected by sex and are increased in females more than males in patients with diabetes. Among individuals aged 50–75 years without baseline diabetes, CKD or CV disease, males have a steeper decline in glomerular filtration rate (GFR) than females.3 However, reported effects of sex on risk of incidental and progressive CKD in patients with type 2 diabetes (T2D) have been inconsistent. In trials including patients with CKD, female representation varies (25%–40%),whereas in real-world studies, females make up over half of patients.engAtribución/Reconocimiento-NoComercial 4.0 Internacionalhttps://creativecommons.org/licenses/by-nc/4.0/Enfermedades RenalesDiabetes Mellitus Tipo 2Ensayo Clínico Fase IIIjournal article10.1136/bmjopen-2023-076444open accessInvestigación médicaSistema cardiovascularTratamiento médicoGoal 3: Ensure healthy lives and promote well-being for all at all ages